1. Kavurus M.S. and Wiedeman H.P: Definition and classification. 2da Ed. Professional comunications: 2006 ; 2-3. 2. Edelman N.H and Carpi J : What is Asthma. Family guide to asthma and allergies. American Lung Association L.B 1998; 7-12. 3. Grupo Latinoamericano para el estudio y tratamiento del asma: Epidemiología. Consideraciones prácticas para el diagnóstico y tratamiento del asma. Caracas 2000; 10-11. 4. Picado V. C: Inflamación en el Asma Bronquial. Barcelona 1992. 5. Edelman N.H and Carpi J: Treating asthma in children. Family guide to asthma and allergies American Lung Association. L.B 1998; 58-73. 6. Kavurus M.S. Pathogenesis: Role of airway inflamation and airway reactivity 1999; 4-5. 7. Buist AS, Vollmer WM. Preventing deaths from asthma. N Engl. Med 1994; 331: 1584-5. 8. Banner. The increase in asthma prevalence. Chest 2001;108(2):301-2. 9. Mohapata SS. Será mejor la prevención que la curación de las alergias y asma en los primeros 20 años del siguiente siglo. Rev Alerg Mex 1995; 42 (2): 18-9. 10.OPS. Estadísticas de Salud en las América.1992; Washington: OPS.387. 11. Dirección Nacional de Estadísticas. Boletín Estadístico 1996. No.3. 12. Farreras: Asma Bronquial. Fisiopatología. Sec 5. Neumología. 14ed. Cap 95. 2000. 13. Kavurus M.S. and Wiedeman H.P: Diagnosis and management of asthma. 2ed Proffessional Comunications 2006; 9-10. 14. Meneghello: Mediadores Químicos en enfermedades del aparato respiratorio. Tomo 1, 5taEd. Ed. Panam 1997;1274-75. 15. Elliott MW, Durham SR, Newman Taylor AJ. Pulmonary eosinophilia. En: Walters EH, du Bois RM, eds. Immunology and management of interstitial lung diseases. Londres, Chapman & Hall, 1995; 149-166. 16. Cuss FM, Dixon CM, Barnes PJ. Effects of platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet 2: 986; 189 -192. 17. Spencer DA. An update on PAF. Clin Exp Allergy 22: 1992; 521-524. 18. Kaliner M, Shelhamer J, Davis PB, Smith LJ, Venter JC. Autonómic nervous system abnormalities and allergy. Ann Intern Med 96: 1982; 349-357. 19.Banes PJ. Neural control of human airways in health and disease. Am Rev Respir Dis 134: 1986; 1289- 1314. 20.Ollerenshaw S, Jarvis D. Substance P immunoreactive nerve fibres in airways from patients with and without asthma. Am Rev Respir Dis 139: 1989; A237. 21. Nelson HS. Beta adrenergic bronchodilators. N Engl J Med 1995; 333: 459-506. 22. Sierra- Monge JJL, Baeza-Bacab MA, Serrano-Sierra A. Tratamiento del asma. Bol Med Infant Mex 1995; 52:443-453. 23. Gross NJ. Ipatropium bromide. N Engl J Med 1988;319:486-494. 24. Bousquet J, Michel R. Asthma. A disease remodeling the airways. Allergy 1992;47:3-11. 25. Juniper EF, Kline PA, Vanzieleghem-Ramsdale EH, O‘Byrne PM, Har-greave FF. Long term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur Res-pir J 1990;3:1122-1127. 26. Knor B, Matz J, Bernstein JA, Nguyen BC, Seidenberg BC, Reiss TF et al. Montelukas for chronic asthma in children 6 to 14 years. JAMA 1998;279:1181-1186. 27. Neuman I, Nahum H, Ben-Amotz A. Reduction of exercise-induced asthma oxidative stress by lycopene, a natural antioxidant. Allergy 2000 Dec;55(12):1184-9. 28. Sánchez, G. M.; Delgado, R.; Pérez, G. D.; Garrido, G.; Núnez-Sellés, A. J.; León, O. S. Evaluation of the in vitro antioxidant activity of Mangifera indica L. extract (QF808). Phytother. Res. 15 (6), 245-2474, 2000. 29. Sánchez, G. M.; Re, L.; Giuliani, A.; Núnez-Sellés, A. J.; Pérez-Davison, G.; León, O. S. Protective effect of Mangifera indica L. Extract, mangiferin and selected antioxidants against TPA-induced biomolecules oxidation and peritoneal macrophage activation in mice. Pharmacology Research 42 (6): 555-573, 2000. 30. Sánchez, G. M.; Giuliani, A.; León, O. S.; Pérez-Davison, G. D.; Núñez-Sellés, A. J.; Effect of Mangifera indica L. Extract (Vimang) on protein and hepatic microsomes peroxidation. Phytotherapy Research 15 (7): 581-585, 2001. 31. Sánchez, G. M.; Candelario-Jalil, E.; Giuliani, A.; León, O. S.; Sam, S. R; Delgado, R.; Núnez-Sellés, A. J. Mangifera indica L. extract (Vimang) reduces ischemia-induced neuronal loss and oxidative damage in the gerbil brain. Free Rad. Res. 35 (5): 465-473, 2001. 32. Sánchez, G. M.; Rodríguez, M.; Núnez-Sellés, A. J.; Pons, N.; Sam, S. R; León, O. S. Protective effect of Mangifera indica L. extract on the injury associted with hepatic ischemia reperfusion. Phytother Res . 17,197-201, 2003. 33. Núñez SA, Páez BE, Amaro GD, Acosta EJ, Agüero AJ, Capote HR, y col. Composiciones farmacéuticas y suplementos nutricionales a partir de extractos de Mangifera indica L. Patente con Certificado No: 22846 OCPI 2002. 34. Nuñez Sellés, AJ Vélez, H Agüero, J González, J Naddeo, F, De Simone, F, Rastrelli, L. “Isolation and quantitative análisis of phenolic antioxidants, free sugars, and polyols from mango ( Mangifera indica L) ítem bark aqueos decoction used in Cuba as nutricional supplement”. (2002) J Agric Food Chem 50: 762-766. 35. García D, Delgado R, Ubeira F.M, Leiro J. Modulator efects of rat macrophage function by Mangifera indica L extract (Vimang) and mangiferin. International Immunopharmacology 2 (6): 797-806, 2002. 36. Garrido G, González D, Delporte C, Backhouse N, Quintero G, Nuñez-Sellés A, Morales M. Analgesic and Anti-inflammatory Effects of Mangifera indica L. extract (Vimang). Phytother. Res. 15, 18–21 2001. 37. Delgado R; Garrido G. et al: Mangifera Indica L. Extract (Vimang) as a natural antioxidant with antinociceptive and antiinflamatory properties. Minerva Med: 2001; 92: 98-102. 38. Bowler RP, Crapo JD. Oxidative stress in airways: is there a role for extracellular superoxide dismutase? Am J Respir Crit Care Med 2002 Dec 15;166(12 Pt 2):S38-43. 39. Henricks PA, Nijkamp FP. Reactive oxygen species as mediators in asthma. Pulm Pharmacol Ther 2001;14(6):409-20. 40. MacNee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol 2001 Oct 19;429(1-3):195-207. 41. Nadeem A, Chhabra SK, Masood A, Raj HG. Increased oxidative stress and altered levels of antioxidants in asthma. J Allergy Clin Immunol 2003 Jan;111(1):72-8. 42. Wood LG, Gibson PG, Garg ML. Biomarkers of lipid peroxidation, airway inflammation and asthma. Eur Respir J 2003 Jan;21(1):177-86. 43. Alina Álvarez León, Alfredo Jane Lara, Juana M. Rodríguez Cutting, Marlen Izquierdo González, Natalia Luisovna Planas Sliuntiaeva, Carmen E Viada González, Annia Riaño Montalvo, Gledys Reynaldo. Evaluación clínica del efecto antiinflamatorio del extracto de Mangifera indica L (VIMANG®) en pacientes con diagnóstico de asma bronquial. Informe final (ensayo clínico 1era etapa). CQF. 2005 44. Gil del Valle L, Martínez G, Gonzalez Blanco I, Tarinas A, Alvarez A, Molina R, Robaina M, Tapanes R, Perez Avila J, Guevara M, Nuñez Selles A, Leon OS. Effects of Vimang on oxidative stress and marker of disease progression in HIV-AIDS patients. Free Radic Res 2002; 36: 107-108. 45. Pardo-Andreu GL, Philip SJn, Riaño A, Sánchez C, Viada C, Núñez-Sellés AJ, Delgado R. Natural extract from stem bark of Mangifera indica L. (Vimang) protects against serum oxidative stress related with age in elderly humans. Arch Med Res 2006; 37: 158-164. 46. Alberto J. Núñez Sellés, Gabino Garrido Garrido, René Delgado Hernández, Gregorio Martínez Sánchez, Gilberto L. Pardo Andreu, Dagmar García Rivera, Patricia Hernández Casaña, Idania Rodeiro Guerra, Mariela M. Guevara García,Alina Álvarez León, Beatriz Garrido Suárez, Reymundo Miranda Leyva.VIMANG?. EXTRACTO DE LA CORTEZA DEL ÁRBOL DEL MANGO (Mangifera indica L.).UN RETO EN LA TERAPIA ANTIOXIDANTE. (Libro para editar) 47. Alvarez-León A, Sánchez-Baldoquín C, Rivera DG, Rodríguez-Morales J, Lemus-Molina Y, Jane-Lara A, Rodríguez-Cutting JM, Izquierdo-González M , Sanz-Larruga ML. Treatment of bronchial asthma with aqueous an extract of Mangifera indica L. (VIMANG®): two cases report. Journal of Medical Case Reports (submitted) 48. García D, Escalante M, Delgado R, Ubeira FM, Leiro J. Anthelminthic and antiallergic activities of Mangifera indica L. stem bark components Vimang and mangiferin. Phytother Res 2003 b, 17: 1182-1187. 49. Negrao-Correa, D., Adams, L.S., Bell, R.G. (1999). Variability of the intestinal immunoglobulin E response of rats to infection with Trichinella spiralis, Heligmosomoides polygyrus or Nippostrongylus brazilinesis. Par. Immunol., 21: 287-297. 50. Gámez R, Mas R, Arruzazabala M, Noa M. Estudios de toxicidad por dosis únicas del Vimang en roedores: Ratas Sprague Dawley y ratones OF-1. Reporte Final de estudios toxicológicos. 2001; 6-38. 51.Gámez R, Mas R, Arruzazabala M, Noa M. Estudio de la toxicidad subcrónica oral (Estudio de los 90 días) del Vimang en ratas Sprague Dawley. Reporte Final de estudio toxicológico. 2002; 8-39. 52. American Toracic Society Medical Seccion of the American Lung Association. Standardization of espirometric 1994 update. And J Resp Crit Med 1995; 152:1107- 1137. 53. American Toracic Society Medical Seccion of the American Lung Function Testing: Selection of referencies Values and Estrategies. And Rev Respir Disease 1991;144:1202-1218. 54. Jané A,et al. Ecuaciones de Predicción derivadas de la Espirometría. Rev Cub Hosp Militares 2007 (En prensa). 55. Cherniack RM, Raber MB. Normal standards for ventilatory function using an automated wedge spirometer. Am Rev Dis 1972; 106:38-44. 56. Morris J.T, Koshi A.,Johnson LC. Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis 1971;103 (1): 57-67. 57.Tinker CM. Peak expiratory flow measured by the Wright peak flowmeter. Distribution of values in men aged 30-59 who denied respiratory symptoms. Br Med J 1961; 1:1365-1366.
Versión para impresión